News
AB Science receives US FDA & EMA authorization for confirmatory phase 3 trial of masitinib in metastatic castrate resistant prostate cancer: Paris Monday, July 7, 2025, 11:00 Hrs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback